QIAGEN Takeover Proposal Highlights Investment in Life-Sciences Technology

On 21 October, EQT’s acquisition vehicle announced a proposed cash offer for QIAGEN at €46.50 per share, representing an equity valuation of approximately €9.6 billion. QIAGEN develops sample and assay technologies used in molecular testing, but the proposed transaction is a corporate acquisition rather than a new hospital, medical-tourism or clinical-services contract. Healthcare providers and research organisations can explore clinical-data analysis, laboratory analytics and research computing; HPC can support suitable data-intensive workloads, with quotations based on confirmed technical needs.

If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.